Last reviewed · How we verify
NCT03742687
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
NA trial testing Heterogeneously Hypofractionated Radiotherapy in Stage III Non-small-cell Lung Cancer in 151 participants. Currently enrolling.
30 December 2023
Quick facts
| Lead sponsor | Danish Lung Cancer Group |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 151 |
| Start date | 22 November 2018 |
| Primary completion | 30 December 2023 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Heterogeneously Hypofractionated Radiotherapy
Conditions studied
- Stage III Non-small-cell Lung Cancer — all drugs for Stage III Non-small-cell Lung Cancer →
- Stage IV Non-small Cell Lung Cancer — all drugs for Stage IV Non-small Cell Lung Cancer →
- Radiotherapy Side Effect — all drugs for Radiotherapy Side Effect →
Sponsor
Danish Lung Cancer Group
Who can join
18 and older, any sex, with Stage III Non-small-cell Lung Cancer or Stage IV Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The options for patients with locally advanced non-small cell lung cancer (NSCLC) who are not candidates for a standard definitive chemoradiotherapy regime are meagre. These are patients who are not fit for a chemoradiotherapy schedule of 66 Gy in 2 Gy fractions due to either tumour extent, resulting in excessive dose to the healthy tissue in the thorax, or with performance status not supporting seven weeks of intensive treatment. The aim is to study the efficiency as well as the safety of a new treatment option of heterogeneously hypofractionated radiotherapy for patients with locally advanced NSCLC who are not candidates for standard, high-dose chemoradiotherapy, either due to excessive irradiation of normal tissue (defined as category A patients) or due to fragility of the patient (category B patients).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Management of locally advanced non-small cell lung cancer: State of the art and future directions.
Miao D, Zhao J, Han Y, Zhou J, et al · · 2024 · cited 99× · PMID 37985191 · DOI 10.1002/cac2.12505
Verify or expand the search:
- PubMed search for NCT03742687
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stage III Non-small-cell Lung Cancer
Currently open trials in the same condition.
- NCT04085250 — Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Defi · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03742687 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Danish Lung Cancer Group
- Last refreshed: 11 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03742687.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing